News on research and diagnostic development for pathogenic diseases.
Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.
While the news of the BARDA contract drove a surge in T2's stock price, it was last month's NTAP decision that has company officials and analysts encouraged.
The test detects 20 common viruses and bacteria that cause upper respiratory infections using the firm's high-throughput, automated MDx-3000 instrument.
Researchers identified Streptococcus pyogenes isolates from a lineage dubbed M1UK that are predicted to produce higher-than-usual levels of a scarlet fever-associated toxin.
The funding is being provided by the Flemish government's Agency for Innovation and Entrepreneurship to support the three-year development project.
